Chimeric Therapeutics Ltd. (AU:CHM)
ASX:CHM
Top Page
Chimeric Therapeutics Ltd.
(Sydney:CHM)
Select Model
Select Model
Rating:45Neutral
Price Target:
AU$0.01
â–˛(10.00% Upside)
Action:ReiteratedDate:12/30/25
The score is primarily constrained by weak financial performance: ongoing losses, continued cash burn, and a materially reduced equity cushion. Offsetting factors include high recent gross margins and no reported debt. Limited technical data prevents a stronger technical read, and valuation is challenged by negative earnings and no dividend support.
Positive Factors
FDA Orphan Drug Designation
The FDA Orphan Drug Designation provides market exclusivity and tax incentives, strengthening Chimeric's competitive position in cancer therapy.
Negative Factors
Ongoing Cash Burn
Continued cash burn indicates reliance on external funding, which could lead to dilution and financial instability if not addressed.
Read all positive and negative factors
Positive Factors
Negative Factors
FDA Orphan Drug Designation
The FDA Orphan Drug Designation provides market exclusivity and tax incentives, strengthening Chimeric's competitive position in cancer therapy.
Read all positive factors
Chimeric Therapeutics Ltd. (CHM) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$8.84M
Dividend YieldN/A
Average Volume (3M)3.63M
Price to Earnings (P/E)―
Beta (1Y)0.99
Revenue GrowthN/A
EPS Growth46.28%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding4,418,703,600
10 Day Avg. Volume3,014,500
30 Day Avg. Volume3,625,345
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.74
Price to Sales (P/S)1.36
P/FCF Ratio-0.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Chimeric Therapeutics Ltd. Business Overview & Revenue Model
Company Description
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies in oncology in Australia. The company develops CHM 0201 (core NK platform) that is in phase I clinical trial for treating s...
How the Company Makes Money
Chimeric Therapeutics makes money primarily through the development and commercialization of its CAR-T cell therapy products. The company's revenue streams include licensing agreements, where it partners with other pharmaceutical companies to co-d...
Chimeric Therapeutics Ltd. Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
46
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.57M | 3.97M | 7.46M | 0.00 | 2.62M | 2.65K |
| Gross Profit | 2.66M | 3.12M | 7.45M | 3.54M | 1.67M | -844.31K |
| EBITDA | -8.60M | -9.08M | -11.30M | -28.59M | -13.62M | -14.26M |
| Net Income | -15.00M | -10.43M | -12.53M | -25.92M | -15.90M | -15.11M |
Balance Sheet | ||||||
| Total Assets | 5.93M | 21.57M | 15.27M | 22.38M | 34.88M | 36.50M |
| Cash, Cash Equivalents and Short-Term Investments | 2.50M | 5.76M | 3.05M | 5.37M | 18.38M | 22.41M |
| Total Debt | 0.00 | 0.00 | 3.59M | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 8.96M | 19.60M | 12.80M | 16.71M | 9.17M | 11.37M |
| Stockholders Equity | -3.03M | 1.97M | 2.47M | 5.66M | 25.71M | 25.13M |
Cash Flow | ||||||
| Free Cash Flow | -6.15M | -7.28M | 10.11K | -16.43M | -13.69M | -14.15M |
| Operating Cash Flow | -6.15M | -7.28M | -7.54M | -16.32M | -13.15M | -8.84M |
| Investing Cash Flow | -255.31K | 0.00 | 0.00 | -112.19K | -577.86K | -5.30M |
| Financing Cash Flow | 6.28M | 10.05M | 8.26M | 253.38K | 9.50M | 36.54M |
Chimeric Therapeutics Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$6.76M | -3.15 | -17.07% | ― | ― | 71.10% | |
48 Neutral | AU$112.42M | -14.80 | -40.65% | ― | 700.00% | 26.88% | |
45 Neutral | AU$8.84M | -0.15 | 2844.96% | ― | ― | 46.28% | |
43 Neutral | AU$19.66M | -3.69 | 2509.60% | ― | ― | -36.89% | |
42 Neutral | AU$58.88M | -5.28 | -62.49% | ― | ― | 10.78% | |
41 Neutral | AU$138.81M | -2.84 | 279.21% | ― | ― | 0.66% |
* Healthcare Sector Average
AU:CHM
Chimeric Therapeutics Ltd.
―
―
―
AU:PTX
Prescient Therapeutics Limited
0.06
0.01
33.33%
AU:IXC
Invex Therapeutics Ltd.
0.09
0.02
28.57%
AU:NOX
Noxopharm Ltd.
0.06
>-0.01
-7.25%
AU:RCE
Recce Pharmaceuticals Ltd.
0.48
0.19
67.25%
AU:ALA
Arovella Therapeutics Limited
0.09
0.01
13.41%
Chimeric Therapeutics Ltd. Corporate Events
Chimeric Therapeutics Issues 309.9 Million New Shares Under Regulatory Notice
Jan 7, 2026
Chimeric Therapeutics has issued 309,900,722 new ordinary shares on 7 January 2026, expanding its share capital without providing a prospectus-style disclosure under the Corporations Act provisions governing fundraising. The company affirmed it is...
Chimeric Therapeutics Seeks ASX Quotation for 309.9 Million New Shares
Jan 7, 2026
Chimeric Therapeutics Limited has applied to the ASX for quotation of 309,900,722 ordinary fully paid shares, to be issued and quoted from 7 January 2026 under its existing ticker CHM. The large issuance, tied to previously announced transactions,...
Chimeric Therapeutics Announces Change in Substantial Holding After Share Placement
Jan 5, 2026
Chimeric Therapeutics has disclosed that Paul Hopper has ceased to be a substantial shareholder in the company as of 31 December 2025, following the filing of a statutory notice. The change in substantial holding status arises solely from dilution...
Chimeric Therapeutics Issues 466.7 Million New Shares Under Section 708A
Dec 31, 2025
Chimeric Therapeutics has issued 466,666,665 new ordinary shares on 31 December 2025, expanding its share capital without providing a prospectus or other disclosure document, in reliance on the provisions of section 708A of the Corporations Act. T...
Chimeric Therapeutics Seeks ASX Quotation for 466.7 Million New Shares
Dec 31, 2025
Chimeric Therapeutics Limited has applied for quotation on the ASX of 466,666,665 new fully paid ordinary shares, to be issued on 31 December 2025 under its existing capital management program. The substantial increase in quoted securities signals...
Chimeric Therapeutics Plans Major Capital Raise via Shares, Notes and Options
Dec 23, 2025
Chimeric Therapeutics Limited has announced a proposed capital raising via a placement and related securities issue, seeking to issue up to 690,099,278 new fully paid ordinary shares, 4,000,000 convertible notes, and a substantial number of option...
Chimeric Therapeutics Issues 16.7 Million Unquoted Options Under Employee Incentive Scheme
Dec 19, 2025
Chimeric Therapeutics Limited has notified the market of the issue of 16,667,000 unquoted options under an employee incentive scheme, with various exercise prices and expiry dates, effective 12 December 2025. The additional unquoted equity securit...
Chimeric Therapeutics Grants 16.7 Million Unlisted Options to Director Miles Prince
Dec 19, 2025
Chimeric Therapeutics has disclosed a change in director Miles Prince’s interests, confirming the issue of 16,667,000 unlisted options to him following shareholder approval at the company’s 25 November 2025 Annual General Meeting. The ...
Chimeric Therapeutics Shares Halted Ahead of Material Capital Raising Announcement
Dec 19, 2025
Chimeric Therapeutics has requested and been granted a trading halt on its securities by the ASX as it prepares to announce details of a material capital raising. The halt will remain in place until the anticipated announcement is released or unti...
Chimeric Therapeutics’ CHM 1107 Receives FDA Orphan Drug Designation for Gastric Cancer
Dec 7, 2025
Chimeric Therapeutics announced that its novel CAR-T cell therapy, CHM 1107, has been granted Orphan Drug Designation by the FDA for the treatment of gastric cancer. This designation provides the company with incentives such as tax credits and pot...
Chimeric Therapeutics Announces Board Changes and Promising Trial Results
Nov 27, 2025
Chimeric Therapeutics announced significant board changes following shareholder feedback from its recent AGM, including the appointment of a new Chairperson and a Non-Executive Director nominated by a major shareholder. The company is optimistic a...
Chimeric Therapeutics Announces Director Resignation
Nov 26, 2025
Chimeric Therapeutics Ltd. announced the resignation of Paul Hopper from his position as a director, effective November 25, 2025. This change in the board may impact the company’s strategic direction and investor confidence, given HopperR...
Chimeric Therapeutics AGM Results and Leadership Changes
Nov 25, 2025
Chimeric Therapeutics Ltd. announced the results of its Annual General Meeting, where all resolutions were conducted via poll. A significant outcome was the ‘first strike’ against the Remuneration Report under the Corporations Act, ind...
Chimeric Therapeutics Highlights Risks in Clinical Trials and Regulatory Processes
Nov 24, 2025
Chimeric Therapeutics Ltd. has issued a news release containing forward-looking statements, highlighting potential risks and uncertainties related to their clinical trials and regulatory approvals. The announcement underscores the company’s ...
Chimeric Therapeutics Secures $4.5M R&D Tax Incentive to Boost Cancer Therapy Development
Nov 24, 2025
Chimeric Therapeutics has received a $4.5 million RD tax incentive from the Australian Government, recognizing its research and development activities in 2025. This financial boost supports Chimeric’s ongoing efforts in advancing its cell th...
Chimeric Therapeutics Reports Promising Results in CHM CDH17 Clinical Trial
Nov 13, 2025
Chimeric Therapeutics announced promising results from its CHM CDH17 Phase 1/2 clinical trial, showing 75% disease control among evaluable subjects at 28 days. The trial, which focuses on advanced colorectal cancer, gastric cancer, and gastrointes...
Chimeric Therapeutics Temporarily Halts Phase 1b Trial Due to Supply Chain Issues
Nov 13, 2025
Chimeric Therapeutics has temporarily suspended its CHM CORE-NK + Vactosertib Phase 1b clinical trial due to supply chain issues unrelated to the treatment itself. The trial aims to treat patients with advanced colorectal and blood cancers, and th...
Chimeric Therapeutics Reports Promising ADVENT-AML Trial Results
Nov 6, 2025
Chimeric Therapeutics Limited responded to an ASX query regarding the ADVENT-AML clinical trial results. The company disclosed that no dose-limiting toxicities were observed, and CORE-NK cells persisted in patients’ blood. Notably, 57% of hi...
Chimeric Therapeutics Advances Clinical Trials and Expands Leadership
Oct 31, 2025
Chimeric Therapeutics has reported significant progress in its CHM CDH17 Phase 1/2 clinical trial, advancing to dose level 2 with promising safety and efficacy results. The trial has shown manageable safety profiles and encouraging disease control...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.